How to Learn Type III Secretion Injectisomes: From Basal-Body Assembly to Needle Gating, Translocons and Hierarchical Effector Delivery

## Wait, What? A Bacterium Can Build a Hollow Needle and Use It as a Protein Delivery Machine Some Gram-negative bacteria assemble a Type III secretion system, or **T3SS injectisome**. The machine spans the bacterial inner and outer membranes. It builds an extracellular needle or filament. When the distal tip contacts a suitable target membrane, secreted translocator proteins can form a pore. Effector proteins can then cross from bacterial cytoplasm toward the target-cell interior. The core reasoning chain is: > **export apparatus → basal body → inner rod → needle → tip → translocon → effector secretion** But assembly is not enough. The machine must also decide: > **which substrate goes first, when needle construction stops, when translocators replace needle proteins, and when effectors become eligible for secretion** ## The One-Sentence Answer **Learn the Type III injectisome as a hierarchical protein-export nanomachine: an inner-membrane SctRSTUV export apparatus and ring-shaped basal body nucleate a narrow secretion conduit, SctF-type subunits build the needle while SctP/SctU help control length and substrate switching, a distal SctA tip coordinates SctB/SctE translocon formation in the target membrane, and cytosolic sorting/chaperone machinery feeds secretion-competent substrates into an export gate powered by both ATP-dependent preparation and proton-motive-force-coupled translocation.** ## Learning Ladder **Beginner:** some bacteria use a tiny needle-shaped machine to deliver proteins into nearby cells. **Secondary / Pre-University:** membranes, proteins, ATP, proton gradients, diffusion, host–microbe interaction and molecular machines. **Undergraduate:** SctR/S/T/U/V export apparatus, SctD/J/C basal body, SctF needle, SctP ruler, SctA tip, SctB/E translocators, SctN ATPase and secretion chaperones. **Advanced / Professional:** export-apparatus stoichiometry, SctU substrate switching, SctV docking, needle-length control, PMF coupling, ATPase/chaperone hierarchy, translocon insertion, host-contact activation and evolutionary relationship with the flagellar Type III export apparatus. — ## Stage 1: Begin With the Topological Problem An effector protein begins in the bacterial cytoplasm. To reach a eukaryotic cytosol, it may need to cross: – bacterial inner membrane; – peptidoglycan/periplasm; – bacterial outer membrane; – extracellular gap; – target-cell membrane. A conventional single membrane transporter is not enough. The injectisome solves a **multi-envelope continuity problem**. ## Stage 2: Type III Secretion Is Not a Vesicle The substrate is not packaged into a membrane vesicle. Instead, protein passes through a narrow proteinaceous conduit. This makes substrate conformation important. Large folded domains cannot simply pass through a needle lumen unchanged. ## Stage 3: The Export Apparatus Is Built First The inner-membrane export apparatus contains: – SctR; – SctS; – SctT; – SctU; – SctV. Modern structural work supports a highly ordered helical core with conserved stoichiometry. This apparatus sits at the centre of the future basal body. ## Stage 4: SctRST Form a Helical Core SctR, SctS and SctT assemble into a compact membrane-associated structure. The assembly has pseudo-helical symmetry rather than a simple flat membrane pore. Its geometry is inherited from the evolutionary relationship between injectisomes and flagellar export systems. ## Stage 5: SctT Helps Keep the Resting Gate Closed A secretion channel cannot remain permanently open. Structural work supports a gated resting state. SctT contributes to a plug-like constriction in the core export apparatus. The machine therefore has an explicit **closed-before-substrate** state. ## Stage 6: SctU Is a Substrate-Switching Protein SctU is an autoprotease-family component of the export apparatus. Its self-cleavage and conformational state contribute to switching substrate preference. This matters because the machine first secretes its own structural parts. Only later does it secrete translocators and effectors. ## Stage 7: SctV Is the Major Cytoplasmic Gate/Sorting Platform SctV forms a large cytoplasmic domain beneath the membrane export apparatus. It interacts with substrates and chaperone–substrate complexes. It is therefore a major point where **secretion eligibility becomes physical docking**. ## Stage 8: The Basal Body Builds Around the Export Apparatus Major ring components include: – SctJ and related inner-membrane/periplasmic rings; – SctD inner-membrane-associated ring; – SctC outer-membrane secretin. The basal body creates a mechanically stable trans-envelope scaffold. ## Stage 9: SctC Forms the Outer-Membrane Secretin SctC-family proteins assemble into large oligomeric outer-membrane pores. This creates the external exit route. The secretin must be aligned with the inner-membrane export apparatus so that the future needle forms one continuous axis. ## Stage 10: The Inner Rod Connects Export Apparatus to Needle SctI-type proteins build an inner-rod structure. The inner rod forms a transition between the basal machinery and the extracellular needle. The machine is therefore not a barrel with a needle attached arbitrarily. It is an ordered axial assembly. ## Stage 11: The Needle Is a Polymer of SctF-Type Subunits Needle subunits are exported through the machine they are constructing. They polymerize at the distal end. This creates a remarkable recursive process: > **the machine exports the parts needed to extend its own conduit** ## Stage 12: Needle Subunits Must Stay Secretion-Competent Some needle proteins use dedicated small chaperones. These prevent premature oligomerization in the bacterial cytoplasm. The chaperone job is not to create the final needle fold. It keeps the substrate in the right pre-export state. ## Stage 13: Needle Length Must Be Controlled A needle that is too short may not reach the target membrane. A needle that is unnecessarily long wastes protein and can reduce mechanical efficiency. SctP-family proteins contribute to length control. The classic metaphor is a molecular ruler. ## Stage 14: “Ruler” Is a Model, Not a Tape Measure SctP length correlates with needle length in several systems. But the protein does not simply lie alongside the completed needle like a literal measuring tape. Its secretion, interactions and timing help create a length-dependent switching mechanism. ## Stage 15: Length Control Is Linked to Substrate Switching When the needle reaches a suitable stage, the secretion hierarchy changes. Early structural substrates are reduced. Middle substrates such as tip/translocator components become favoured. Later, effectors dominate. This is a **state-machine transition**. ## Stage 16: Early, Middle and Late Substrates Solve Different Jobs **Early** – inner rod; – needle; – ruler/switch-related components. **Middle** – tip; – translocators. **Late** – effectors. The order ensures the delivery path exists before cargo is sent. ## Stage 17: The Tip Complex Caps the Needle SctA-family proteins assemble at the distal tip. The tip is not merely decorative. It contributes to target-cell sensing and translocon organisation. In some bacteria, the tip extends into a longer filament. ## Stage 18: Tip Architecture Varies by Lineage Some systems form compact oligomeric tips. Others form extended filaments, such as the EspA filament in enteropathogenic *E. coli*. A single textbook needle-tip geometry should not be universalised. ## Stage 19: 2025 Bordetella Work Shows Tip Structures Can Be Dynamic Recent work on Bordetella Bsp22 highlights regulated filament assembly and turnover at the injectisome tip. This reinforces the idea that distal structures can be dynamic secretion states rather than static end-caps. ## Stage 20: Translocators Form the Target-Membrane Pore Hydrophobic SctB- and SctE-type proteins are secreted after needle assembly. They insert into the target membrane and form a **translocon**. The injectisome now gains continuity across the final membrane barrier. ## Stage 21: A Needle Without a Translocon Is Not Yet a Complete Injection Path The needle lumen ends outside the target membrane. Effector delivery into the target cytosol requires the distal pore. This separates: > **secretion from bacterium** from > **translocation into target cell** ## Stage 22: Host Contact Can Trigger Secretion In several systems, close target-cell contact changes tip/translocon state and activates secretion. The molecular trigger differs by organism. The important systems principle is: > **machine assembly creates competence; environmental contact controls deployment** ## Stage 23: Effector Proteins Carry N-Terminal Secretion Information Type III substrates often contain a non-cleaved N-terminal secretion signal. Unlike Sec signal peptides, these signals are not long hydrophobic membrane-targeting sequences. They are sequence-composition and structural-context signals. ## Stage 24: Many Effectors Also Bind Dedicated Chaperones Small acidic chaperones bind regions downstream of the extreme N terminus. They can stabilize effectors, prevent aggregation, help targeting to sorting machinery and maintain secretion-competent conformation. ## Stage 25: The Chaperone Usually Does Not Travel Through the Needle The chaperone helps prepare and target the substrate in the bacterial cytoplasm. It is released before or during loading. The effector, not the chaperone–effector complex as a whole, enters the narrow secretion conduit. ## Stage 26: SctN Is the Cytosolic ATPase The SctN ATPase associates with cytosolic sorting-platform components. ATP hydrolysis helps dissociate chaperones and prepare substrates for export. But ATPase activity is not the whole energy source for translocation. ## Stage 27: Proton Motive Force Drives the Core Export Step Research across injectisome and flagellar systems shows that proton motive force strongly powers protein export through the membrane apparatus. SctV-related components help couple ion motive force to secretion. The energy division is therefore: > **ATPase → substrate preparation/sorting** > **PMF → major translocation drive** ## Stage 28: ATP and PMF Are Complementary, Not Competing Explanations A system can require ATPase function and PMF simultaneously. The mistake is asking which single energy source is “the” power source. Different molecular steps have different energetic demands. ## Stage 29: Substrates Likely Enter Partially Unfolded The needle channel is narrow. Effectors generally need to unfold or remain partly unfolded to pass. Refolding then occurs after translocation. This explains why chaperones and ATPase-mediated preparation matter. ## Stage 30: Secretion Can Be Extremely Rapid After Activation Once the machine is assembled and target contact occurs, pre-synthesized effector stores can be secreted quickly. The cell therefore separates: – slow machine construction; – rapid deployment. ## Stage 31: Type III Injectisomes and Flagella Share an Evolutionary Core Both systems use homologous export-apparatus and ATPase components. The flagellum exports its own structural subunits. The injectisome exports structural subunits and effectors. The shared ancestry explains molecular similarity without making the machines functionally identical. ## Stage 32: The Flagellar Motor and Type III ATPase Should Not Be Confused Flagellar rotation is powered by stator-driven ion flow. Type III secretion ATPases help substrate processing. Homology in export machinery does not mean the injectisome is a rotating motor. ## Stage 33: Plant-Associated T3SSs Can Use Long Pili Some phytopathogenic systems assemble long extracellular pili that cross the plant cell wall before translocon formation. Environmental architecture therefore shapes the exported structure. The same secretion logic adapts to different target geometries. ## Stage 34: Not Every Type III System Has the Same Trigger Temperature, calcium conditions, host contact and chemical signals can regulate different systems. A mechanism demonstrated in *Yersinia* should not automatically be copied onto *Salmonella*, *Shigella*, *Pseudomonas* or plant-associated systems. ## Stage 35: Injectisome Presence Does Not Prove a Particular Effector Function The machine is a delivery platform. The biological outcome depends on effector repertoire, target cell, timing, expression and immune context. A structural apparatus is not itself the final phenotype. ## Stage 36: Cryo-ET Provides Native Machine Architecture Cryo-electron tomography can visualize injectisomes in bacterial envelopes. This reveals basal bodies, needles and target-cell interfaces in native-like contexts. ## Stage 37: Cryo-EM Resolves Export-Apparatus Stoichiometry High-resolution structures reveal subunit numbers and helical organisation. These data constrain assembly models. They do not by themselves reveal secretion order or rate. ## Stage 38: Live Imaging Adds Dynamics Fluorescence imaging can track assembly, secretion activation, tip behavior and target contact. Structure and live dynamics answer different questions. ## Stage 39: Mutational Epistasis Tests Order If loss of an early component prevents all later assembly, while loss of a late effector leaves needle construction intact, the pathway order becomes experimentally visible. Hierarchical machines are well suited to genetic epistasis. ## Stage 40: The Professional Question Is an Assembly–Switch–Delivery Closure Test Ask: > **Which export-apparatus state formed first, whether the basal body aligned correctly, how needle length was controlled, when SctU/SctV substrate preference changed, whether the distal tip assembled a functional translocon, how chaperones and ATPase prepared effectors, whether PMF drove productive translocation, and whether the delivered protein was actually detected inside the target cell rather than merely secreted outside the bacterium.** ## Evidence: What Proves What? ### Architecture – cryo-EM; – cryo-ET; – crosslinking; – stoichiometric mutants. ### Assembly order – conditional expression; – epistasis; – pulse-chase secretion; – fluorescence localisation. ### Needle-length control – SctP length variants; – SctU mutants; – direct needle measurement. ### Energy coupling – ATPase mutants; – PMF perturbation; – secretion kinetics. ### Translocation – host-cell reporter assays; – translocon mutants; – intracellular effector detection. ## Connections Worth Making ### Protein Trafficking Type III secretion exports proteins without a cleaved Sec-style signal peptide. ### Molecular Motors The sorting ATPase and PMF-coupled export gate divide energetic tasks. ### Evolution Injectisomes and flagellar export apparatus share a deep evolutionary core. ### Membrane Biophysics A translocon converts target-membrane contact into a transient protein-conducting path. ### Systems Biology The machine is hierarchical: construction must precede cargo delivery. ## Misconceptions Worth Hunting – **“The injectisome is a syringe filled with liquid toxin.”** It is a protein export/translocation machine. – **“The needle is built outside and attached later.”** Needle subunits are exported through the growing machine. – **“ATP alone powers the entire secretion event.”** PMF is central to translocation. – **“The chaperone travels with the effector into the host.”** It normally acts before export. – **“A completed needle means effectors can enter the host.”** A functional translocon is still required. – **“SctP literally measures the needle like a ruler laid alongside it.”** Length control is a dynamic secretion-switching process. – **“Type III and Type VI systems are the same kind of injector.”** T3SS is an export machine; T6SS is a contractile projectile. – **“Every T3SS works identically.”** Tip structures, triggers and substrate-control systems vary by lineage. ## Transfer Check A bacterium assembles SctRSTUV but cannot form SctC. Which barrier remains unsolved? **The outer-membrane exit/basal-body completion.** A needle grows indefinitely after an SctP defect. What broader process is likely disrupted? **Needle-length control and the switch from early structural substrates toward later substrates.** Effectors are secreted into medium but cannot enter target cells when SctB/SctE are absent. Which step failed? **Translocon-mediated target-membrane passage.** SctN ATPase is impaired but PMF remains normal. Can secretion still be defective? **Yes, because substrate preparation/sorting is compromised.** PMF collapses while ATP is abundant. Is rapid protein translocation expected to remain normal? **No.** ## How We Know the Learning Has Held A learner should be able to distinguish export apparatus, basal body, needle, tip and translocon; explain SctR/S/T/U/V broadly; explain SctP-linked length control; explain secretion hierarchy; explain chaperone roles; explain SctN versus PMF energy contributions; distinguish secretion from translocation; connect T3SS with flagellar ancestry without merging their functions; and evaluate delivery through direct intracellular-effector evidence. ## Model Limits The Sct nomenclature is a unifying framework, but historical names differ by organism. Needle-length control is not explained by one universally settled model. PMF coupling details at SctV and the export apparatus continue to be refined. Translocon structures are difficult to capture in native target membranes. Host-contact activation differs substantially among species. Structural similarity to flagella does not resolve the exact evolutionary order of divergence. > **Professional T3SS science keeps export-apparatus state + basal-body architecture + needle length + substrate class + tip/translocon state + chaperone/ATPase state + PMF + target-cell delivery visible together.** ## Teaching Guide Teach in this order: **topology problem → export apparatus → basal body → secretin → inner rod → needle → length control → substrate switch → tip → translocon → effector signals → chaperones → ATPase → PMF → host contact → evolutionary flagellar connection → model limits.** Begin with: > “Why would a protein-delivery machine need to secrete its own needle before it is allowed to secrete the proteins the cell actually wants to deliver?” ## Connect This to the eduKate Learning Estate – [Microorganisms, Infection and Immunity](https://edukatesengkang.com/2026/08/28/how-to-learn-microorganisms-infection-immunity-host-pathogen-systems/) – [Type VI Secretion System](https://edukatesengkang.com/2026/08/31/how-to-learn-type-vi-secretion-system/) – [Bacterial Flagellar Motors](https://edukatesengkang.com/2026/08/31/how-to-learn-bacterial-flagellar-motors/) – [Bacterial Sec and Tat Protein Export](https://edukatesengkang.com/2026/08/31/how-to-learn-bacterial-sec-tat-protein-export/) These remain broader or adjacent canonical owners. This article owns **Type III injectisome assembly, secretion hierarchy and target-cell translocation**. ## Research Foundations and Further Learning – Classic and modern reviews of Type III secretion injectisome architecture. – Structural work defining the SctR₅S₄T₁U₁ export apparatus and SctV cytoplasmic gate. – Cryo-EM/cryo-ET studies of basal-body, needle and host-contact states. – Needle-length and secretion-switching studies involving SctP and SctU. – Work on SctN ATPase, chaperone release and PMF-dependent export. – 2025 *mBio* work on dynamic Bordetella injectisome tip-filament assembly. – 2026 eLife work on SctS/SctT translational coupling and export-apparatus stoichiometric assembly. ## The Quiet Ending The beginner asks: “Does the bacterium really inject proteins through a needle?” The developing structural biologist asks: “How does the machine know when to stop building the needle and start sending cargo?” The advanced learner asks: “Why are both ATP and proton motive force involved?” And the professional asks: > **Can we close one full secretion event from export-apparatus assembly to a verified effector molecule inside the target cell, while identifying exactly where substrate hierarchy and energy coupling changed state?**